New 'Four-in-One' antibody tackles tough lymphoma

NCT ID NCT05192486

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This early-stage study tests a new drug called GNC-038 in 12 people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. It is a first step to see if this 'tetra-specific' antibody can control this aggressive blood cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Hebei University

Baoding, Hebei, China
Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shenzhen Second People's Hospital

Shenzhen, Guangdong, China
The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B CELL LYMPHOMA